Alan Landay to Clinical Trials as Topic
This is a "connection" page, showing publications Alan Landay has written about Clinical Trials as Topic.
Connection Strength
0.155
-
Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol. 2000 May; 7(3):352-9.
Score: 0.041
-
An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis. 1997 May; 24(5):764-74.
Score: 0.033
-
Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS. 2015 Apr 24; 29(7):847-51.
Score: 0.029
-
Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study. PLoS One. 2014; 9(1):e85675.
Score: 0.027
-
VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol. 2006 May 25; 7:11.
Score: 0.016
-
Rationale for immune-based therapies for HIV-1 infection. J Lab Clin Med. 1998 Mar; 131(3):197-206.
Score: 0.009